[로피바이오] 연구소장(또는 CTO) 및 책임연구원 & 임상개발 PM (Osong, Korea )

로피바이오는 2015년 오송첨단의료복합단지에 설립되어 바이오의약품 및 바이오시밀러를 개발하는 바이오텍회사입니다. 세포 및 분자과학 분야에서 첨단 기술을 적용해 항체의약품, 유전자치료제, 줄기세포치료제등 바이오신약을 개발하고 있으며, 좀더 단기적인 수익구조 실현을 위해서는 바이오시밀러 개발에도 임하고 있습니다.

바이오신약 중 세포침투형 이중특이 항체 항암제는 암세포만을 선별적으로 침투해 암의 발생, 성장, 전이, 항암제에 대한 내성 개발에 관련요인으로 잘 알려져 있는 pSTAT-3(인산화를 통해 활성화된 STAT-3)와 DNA break repair 작용에 간여하는 RAD51를 동시에 억제함으로써 항암효과의 안전성과 효능성을 성취할 수 있는 차세대 항암제로서 개발 중에 있습니다.

유전자치료제로서는 자가면역성질환인 쇼그렌증후군 치료제로서 AAV벡터를 사용한 RNAi 기반의 치료제로 침샘에 직접투여하는 형태로 개발 중에 있습니다. 그 외에 지방유래줄기세포등의 mesenchymal stem cell therapy개발에도 기술력을 확보해 나가고 있습니다.

바이오시밀러는 Eylea, Keytruda, Opdivo, Humira, Avastin, Rituxan등에 대한 개발이 진행되고 있으며, 황반변성치료제인 Eylea 바이오시밀러의 경우 2022년 글로벌 임상3상에 진입하기 위한 준비 작업을 진행하고 있으며 대만소재 업체와 임상시료 생산에 대한 생산대행업무에 대한 계약과 동시에 중국/동남아시장에 대한 기술이전 및 판관계약을 체결한 바 있습니다.

Rophi는 Rafa와도 같은 뜻으로 ‘치유’라고 하는 의미를 가지고 있습니다. 로피바이오는 치유의 삶을 온누리에 전파하는 것을 기업의 비전으로 삼고 있으며, 그러한 로피바이오의 비전을 함께 실현해 나갈 동역자를 찾고 있습니다.

채용분야 1: 연구소장(또는 CTO) 및 책임연구원

업무내용: 바이오의약품 신약개발, 바이오시밀러 세포주개발, 생산/정제 공정개발, 물리화학적/생화학적 분석등의 각분야에 있어서 석사, 학사 연구원들을 이끌고 연구개발을 진행해 나갈 수 있는 책임연구원 2명 및 R&D 전반적으로 이끌어 주실 연구소장 (또는 CTO).

자격요건: 분자/새포 생물학 및 관련분야 박사학위 보유자

우대사항: 영어 회화 가능자, 신약 또는 바이오시밀러 개발 유 경험자

채용분야 2: 임상개발 PM

업무내용: 로피바이오에서 현재 진행중인 아일리아 바이오시밀러에 대한 글로벌 임상실험을 준비 및 진행업무, CMO/CRO 선정 및 관리업무등

자격조건: 의/약학, 생명과학, 간호학 전공자로서 관련분야 유 경험자, 영어 회화 가능자

우대사항: 석/박사 학위 보유자

채용요건:

근무지: 충북 청주시 오송읍

복지사항: 근무연수 등에 따른 스탁옵션, 청년재직자 내일채움공제, 장기근속포상, 경조사 지원 등

Contact: Sung Ho Hahm, CEO (shahm@rophibio.com)

[MEDIPOST] Senior Director, Head of Cell & Gene-Modified Cell Therapy R&D Center (Pangyo, Korea )

We are looking for a highly motivated scientist to join our company as the Head of Cell Therapy R&D Center to lead 4 research teams developing innovative cell and gene-modified cell therapies.

Reporting to the Management Board of the company, the Head of Cell Therapy R&D Center will be responsible for developments of projects from target discovery through preclinical proof-of-concept, CMC and support of early phase clinical development.

Location:  MEDIPOST HQ located in Pangyo, Gyeonggi-do, Korea (On-site)

Primary Responsibilities

  • Successfully leads cell & gene-modified cell therapy discovery programs;
  • Provides scientific perspective and leadership for cell & gene-modified cell therapy projects of the company’s portfolio through collaboration with other internal departments such as Regulatory Affairs and GMP Manufacturing Facility;
  • Effectively applies best practices to improve operational efficiency;
  • Lead teams of scientists to build cell and gene-modified cell therapy pipelines;
  • Works with leadership team to meet corporate goals.

Qualification

  • PhD with 10+ years of relevant post-doctoral and/or industry experience in cell and/or molecular biology or related field, including 5+ years of relevant experience in managing research teams in a biotech or pharmaceutical R&D environment;
  • In-depth knowledge and hands-on experiences in pre-clinical studies, CMC studies of cell and/or gene-modified cell therapies are required;
  • Strong publication records and presentation skills are preferred;
  • Strong communication skills and team work ethics are required;
  • Capability to translate strategy into action, to successfully manage projects and timelines, organize/track complex information, and prioritize accordingly;
  • Extensive experiences in managing collaborations.

Contact:  Sophia Yang – sophia.yang@medipostamerica.com

About MEDIPOST

MEDIPOST is a Korean company founded in 2000 and became a public company in 2005, listed on KOSDAQ with 300+ current employees. MEDIPOST operates 2 overseas subsidiary companies in Tokyo, Japan and Gaithersburg MD, U.S.

MEDIPOST operates the largest private cord blood bank “CELLTREE®” in Korea with over 255,000 units of private cord blood units under storage. Each year, over 20,000 private cord blood units are collected and stored at CELLTREE®.

MEDIPOST’s research and development is focused on novel off-the-shelf, allogeneic cell therapeutics using human Umbilical Cord Blood-derived Mesenchymal Stromal Cells (hUCB-MSCs) with clinical-stage assets in the disease areas of osteoarthritis (OA), broncho-pulmonary dysplasia (BPD) and Alzheimer’s disease (AD).

MEDIPOST’s flagship product, CARTISTEM® (allogeneic Umbilical Cord Blood-derived MSCs + hyaluronic acid hydrogel composite) for knee osteoarthritis was approved in 2012 by Korea’s regulatory agency Ministry of Food and Drug Safety (MFDS) with Biologics License Application (BLA) label “Treatment of knee articular cartilage defects in patients with osteoarthritis (ICRS grade IV) as a result of degenerative disease or repeated trauma (without age limit)”. To date, over 20,000 patients have been treated on the market with an excellent long-term safety and efficacy profile. CARTISTEM® has also successfully completed the Phase I/II trial in the U.S. and the Phase III trial is planned to commence in 2022. CARTISTEM® is currently undergoing Phase III clinical trial in Japan, while BLA marketing-authorization is under review in Malaysia.

PNEUMOSTEM® (allogeneic Umbilical Cord Blood-derived MSCs) for the prevention of Bronchopulmonary Dysplasia (BPD) in premature infants, completed the first-in-human Phase I safety trial in Korea and the randomized, placebo-controlled Phase II clinical trial is ongoing in Korea. Phase I/II clinical trial in the U.S. has been completed confirming safety with positive efficacy signals. Longer term (3, 4 and 5 year) follow-up on premature infants born with high-risk of developing BPD who received PNEUMOSTEM® demonstrated significant benefit with regards to cognitive development compared to cohort of premature infants who received standard-care alone. PNEUMOSTEM® has received Orphan Drug Designation (ODD) and the Fast-Track Designation (FTD) by the US-FDA and ODD by the EMA.

MEDIPOST’s 2nd generation human Umbilical Cord Blood-derived Mesenchymal Stromal Cell (hUCB-MSC) pipeline code named SMUP-IA-01 is an off-the-shelf intra-articular injectable cell product for the patients with early to mid-stage knee osteoarthritis (OA). SMUP-IA-01 has completed dosing of all 12 subjects in the first-in-human Phase 1 clinical trial in Korea and the 12-months follow-up data demonstrated significant and sustained improvement in subjective pain and knee function assessments in all subjects, with longer-term follow-up planned. Phase 2 randomized controlled trial in Korea will commence in 2022.

SMUP platform is MEDIPOST’s proprietary, patent-protected cell selection and expansion technology using allogeneic umbilical cord blood-derived stem cells as a therapeutic modality. We are looking for qualified and experienced scientists to embark on the exciting journey of developing innovative cell and gene-modified cell therapy programs for unmet medical needs at MEDIPOST.

www.medi-post.com

KOSDAQ ticker: 078160

[CrystalGenomics] 2021 수시채용 (Pangyo, Korea & Orinda, CA)

크리스탈지노믹스㈜에서 KAPAL의 우수한 인재를 모십니다.

인류의 삶의 질(Quality of Life) 개선에 의의를 두고, 함께 세계적인 신약 연구∙개발의 꿈을 실현할 도전적이고 열정적인 인재를 찾습니다.

< 크리스탈지노믹스㈜ 소개 >

당사는 차세대 관절염 치료제, 내성 균주를 박멸하는 신개념 항생제, 분자 표적 항암제와 같이 환자수는 증가하지만 우수한 치료제가 없어 치료에 대한 불만족도가 높은 분야의 혁신 신약 개발에 집중하고 있습니다.

그리하여 질환 표적 단백질의 3차 구조 규명 기술을 포함하는 신약연구개발기술 시스템을 갖추고 신약 개발 파이프라인을 강화하기 위해 최선을 다하고 있습니다.

< 크리스탈지노믹스㈜ 주요 성과 >

– 국내 산학연 최초 신약발굴 기반기술을 활용하여 Nature 표지 논문 게재 (2003)

– 정부의 기술성평가제도 제1호로 코스닥에 상장 (2006)

– 국내 바이오벤처 최초로 혁신 신약 제22호 아셀렉스 승인, 시판 및 수출 (2015)

– 세계적 경쟁력의 신약 발굴 기반 기술로 지속적인 개발후보 발굴

CrystalGenomics, Inc. is headquartered in Pangyo, South Korea and has a U.S. subsidiary (CG Pharmaceuticals, Inc.) in Orinda California for the management of global clinical trials and is publicly traded on the KOSDAQ exchange.

CrystalGenomics is a research-oriented biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of highly unmet medical need.

CrystalGenomics is mainly focused in the therapeutic areas of cancer, infectious disease, pain and inflammation.

For more information, please visit: www.cgxinc.com or www.crystalgenomics.com

CrystalGenomics seeks for the candidates with the traits of integrity, teamwork, excellence, commitment and accountability.

– 지원방법 : 자유양식 (본인을 표현할 수 있는 어떤 형식의 지원도 환영합니다.)

– 문의 및 E-Mail 지원 : ycchoo@cgxinc.com

[NIH, NCI] Seeks Toxicology Specialist (Bethesda, MD)

NCI Seeks Toxicology Specialist

The NCI Division of Cancer Treatment & Diagnosis, Developmental Therapeutics Program, Toxicology and Pharmacology Branch is seeking a candidate with a Bachelors, Masters, and/or Doctoral degree in the field of toxicology, or an appropriate discipline of the biological, medical, or veterinary sciences that includes at least 30 semester hours in chemistry, biochemistry, or physiology, and 12 semester hours in toxicology. The candidate will be responsible for designing segments of toxicology projects and/or studies to support the development of new drugs or biologics; coordinating and evaluating tasks associated with toxicology studies; presenting scientific findings to internal and external stakeholders; and serving as a technical consultant in the area of toxicology.

Qualifications:

Applicants must be U.S. citizens. Grade and salary are dependent upon experience. Knowledge of the principles, theories, and methods of toxicology research activities as relates to new drug development is required.

How to Apply:

Interested candidates should send a letter of application, curriculum vitae, and full contact information for three references to: Elizabeth R. Glaze, Ph.D., D.A.B.T., Chief, TPB, DTP, DCTD, at: glazee@mail.nih.gov.

[순천향대학교] 순천향의생명융합학과, 순천향의생명연구원 (SIMS)연구원 – 교수 채용 공고 (Cheonan-si, Korea)

TENURE-TRACK FACULTY POSITIONS
Department of Integrated Medical Bioscience
Soonchunhyang Institute of Medi-bio Science (SIMS)
Soonchunhyang University
Cheonan-si, Korea
http://www.sims.ac.kr/en/

Soonchunhyang Institute of Medi-bio Science (SIMS) is a newly established research institute by Soonchunhyang University with over $20 million investment. The research focus of SIMS is on metabolism or metabolism-related diseases including obesity, diabetes, immunology, cancer and stem cells. Although SIMS is established only in 2016, we believe that our institute has developed to the largest institute in Korea in the metabolism research field and we currently hold 4 government-sponsored research centers (program projects) with over $4 million supports. SIMS has been also closely collaborating with Soonchunhyang Hospitals and Soonchunhyang Medical School that are located within a working distance from SIMS.

SIMS seek outstanding applicants for a tenure-track Assistant Professor position in the fields of metabolism or metabolism-related research fields including cancer metabolism, immune metabolism and liver diseases, or stem cells. We are particularly seeking highly motivated individuals who are working on basic aspects of the research on metabolic diseases and stem cells with potential developments for the translational research areas.

Successful candidate will receive generous start-up packages and laboratory space. Also, the candidate will participate Metabolic Disease Tissue Homeostasis Research Center (MHRC) that is one of Reginal Leading Research Centers. The department offers exceptional resources in many areas with a government-sponsored state-of-the-art core facility, equipped with several flow cytometers, IVIS, micro CT, confocal microscope, DEXA, metabolic cages, 10X Genomics, and others. A list of detailed equipment and other information about SIMS can be found at the SIMS homepage (http://www.sims.ac.kr/en/).

Applicants should have a PhD or equivalent degree and several years of postdoctoral experience with a history of high-impact publication. Detailed qualifications and submission guidelines can be found at the Soonchunhyang University homepage (https://home.sch.ac.kr/sch/06/010100.jsp :Notice #7660). The application due date is by 4:00 PM, November 18, 2021 (KST).

If you have any questions regarding this position, please do not hesitate to contact the Administration Office at SIMS (sims@sch.ac.kr or Tel: 82-41-413-5000) or Jongsoon Lee, Ph.D. (Jongsoon.lee@sch.ac.kr).